Isomorphic Labs

Isomorphic Labs is a Pharmaceutical Products startup based in London, England, United Kingdom that has raised $600M in venture capital across 1 funding round since 2021. The company reached Growth stage in April 2025 with a $600M round led by Thrive Capital. Isomorphic Labs's investor base includes 3 institutional funds, with Thrive Capital leading the most recent equity round.

Isomorphic Labs is a British AI-powered drug discovery company spun out of Alphabet's Google DeepMind in February 2021. Founded by Nobel Prize laureate Sir Demis Hassabis — who also serves as CEO of Google DeepMind — the company's mission is to deploy frontier artificial intelligence to accelerate the discovery of novel medicines and ultimately address all disease. The company builds upon DeepMind's AlphaFold research, which achieved breakthrough protein-structure prediction, and extends that science into end-to-end drug design. Its proprietary Drug Design Engine, announced in February 2026, doubles the performance of AlphaFold 3 on protein-ligand structure prediction benchmarks, enabling researchers to model how small molecules bind to disease targets with unprecedented accuracy. In January 2024, Isomorphic Labs signed multi-year research collaborations with Novartis and Eli Lilly — two of the world's largest pharmaceutical companies — to apply its platform to their drug pipelines, validating the commercial potential of AI-native drug discovery. A subsequent collaboration with Johnson & Johnson followed. The company also opened a second research office in Lausanne, Switzerland in December 2022 to access European scientific talent. Isomorphic Labs entered its first oncology programmes into human clinical trials in early 2026, marking a pivotal transition from pure platform to pipeline company. In April 2025, the company closed a $600 million Series A round led by Thrive Capital — its first external funding — with participation from GV (Google Ventures). As of May 2026, Isomorphic Labs is in advanced discussions to raise more than $2 billion in a follow-on round, again led by Thrive Capital, which would place it among the most heavily capitalised AI drug discovery companies globally.